Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


Relevance of early poststress variation in left ventricular function studied by gated-SPECT: evaluation in different clinical settings and relationship with angiography results.

Barone R, Pau FM, Menghini ML, Perino M, Scappaticci M, Ghilardi P, Schiavo B.

Nucl Med Commun. 2014 Aug;35(8):824-31. doi: 10.1097/MNM.0000000000000125.


Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts.

Walrand S, Barone R, Pauwels S, Jamar F.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1270-80. doi: 10.1007/s00259-011-1744-x. Epub 2011 Feb 12.


Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.

Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.

Nucl Med Commun. 2008 Mar;29(3):283-90. doi: 10.1097/MNM.0b013e3282f3d03e.


Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.

Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP.

Semin Nucl Med. 2006 Apr;36(2):147-56.


Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.

de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, Pauwels S.

J Nucl Med. 2005 Oct;46(10):1696-700.


Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.

Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M.

Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1136-43. Epub 2005 May 24.


Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line.

Barone R, Van Der Smissen P, Devuyst O, Beaujean V, Pauwels S, Courtoy PJ, Jamar F.

Kidney Int. 2005 Mar;67(3):969-76.


Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S.

J Nucl Med. 2005 Jan;46 Suppl 1:99S-106S.


Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, Krenning EP, Jamar F.

J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S. Review.


Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP.

J Nucl Med. 2005 Jan;46 Suppl 1:83S-91S.


99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study.

Signore A, Annovazzi A, Barone R, Bonanno E, D'Alessandria C, Chianelli M, Mather SJ, Bottoni U, Panetta C, Innocenzi D, Scopinaro F, Calvieri S.

J Nucl Med. 2004 Oct;45(10):1647-52.


Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues.

Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, Bouterfa H, Devuyst O, Jamar F.

Nephrol Dial Transplant. 2004 Sep;19(9):2275-81. Epub 2004 Jul 13.


86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion.

Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S.

Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):510-8. Epub 2003 Feb 12.


Supplemental Content

Loading ...
Support Center